SCHEMBL1472632

SCHEMBL1472632

COCCOCc1cccc(-c2ccc3nc(-c4cccc(C#N)c4)cn3c2)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 11/20 0.62
NR4A2 P43354 5/20 0.46
CYP2C9 P11712 2/20 0.46
KCNH2 Q12809 2/20 0.46
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
APP P05067 1/20 0.40
ALDH1A2 O94788 1/20 0.39
SLC2A1 P11166 1/20 0.39
ALOX12 P18054 1/20 0.38
GBA1 P04062 1/20 0.37
UGCG Q16739 1/20 0.37
GBA2 Q9HCG7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472147 0.85 ALDH1A3 (0.48) ALDH1A3NR4A2CYP2C9KCNH2ALDH1A1
SCHEMBL1475024 0.81 ALDH1A3 (0.72) ALDH1A3NR4A2CYP2C9KCNH2ALDH1A1
SCHEMBL3429788 0.80 NR4A2 (0.44) ALDH1A3NR4A2CYP2C9KCNH2ALDH1A1
SCHEMBL3410418 0.77 NR4A2 (0.42) ALDH1A3NR4A2CYP2C9KCNH2ALDH1A1
SCHEMBL13270323 0.77 ALDH1A3 (0.65) ALDH1A3NR4A2CYP2C9KCNH2ALDH1A1
SCHEMBL1472923 0.77 ALDH1A3 (0.58) ALDH1A3NR4A2CYP2C9KCNH2ALDH1A1
SCHEMBL1472161 0.76 ALDH1A3 (0.70) ALDH1A3NR4A2CYP2C9KCNH2ALDH1A1
SCHEMBL2773842 0.75 GLA (0.48) ALOX12
SCHEMBL30807351 0.75 GLA (0.48) ALOX12
SCHEMBL3431818 0.74 NR4A2 (0.49) ALDH1A3NR4A2CYP2C9KCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US claimed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NCOR1, NR4A2, NR4A3 ALDH1A3 1043/4885NR4A2 2/4885CYP2C9 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.